Optimind Provides Update on Health Canada’s Dealer License under Joint-Venture with Manitari Pharma
Manitari Pharma received approval to begin construction of Security Level 3 safe + grow rooms
Manitari Pharma is one step closer to obtaining Controlled Substances Dealer’s Licence for Psilocybin Research
TORONTO – Optimind Pharma Corp. (CSE:OMND (“Optimind” or the “Company”), an emerging provider of psychedelic therapies, today provides an update on the Company’s joint venture with Manitari Pharma Corporation (“Manitari Pharma”), which is 40% owned by Optimind.
Manitari Pharma, which has submitted an application to Health Canada for a Controlled Substances Dealer’s License for Psilocybin Research Purposes, has begun the process of permitting and planning the buildout of its facility in accordance with the guidance of Health Canada. Health Canada has approved Manitari Pharma’s plan, pending final inspection, to install a Security Level 3 vault and grow rooms based on the Health Canada Directive on Physical Security Requirements for Controlled Substances and Drugs. A Dealer’s License would permit Manitari Pharma to perform the following activities: procure controlled substances, including by import, synthesis, propagation, cultivation, and harvesting of psychedelic mushrooms for Psilocybin extraction; research and manufacture controlled substances such as Psilocybin and Psilocin; business-to-business sale of controlled substances, including by export; and sale of controlled substances via pharmacies.
“We congratulate Manitari Pharma on being one step closer to a obtaining a Dealer’s License and Optimind looks forward to continue working with Manitari Pharma as it develops treatments for qualifying patients that desperately need psychedelic-enhanced therapy to get better,” commented Tomas Sipos, Chief Executive Officer at Optimind.
“I am proud to announce that Health Canada has approved Manitari Pharma’s site plans for our Dealer’s License. We are in the final stages of construction and expect to have our license by summers end. This will have a substantial impact in the psilocybin space and in helping secure psilocybin’s use in the treatment of mental health conditions. This is vital in expanding our mission in ensuring the future mental health of First Nations and the global community at large,” commented Anna Freeman, Chief Executive Officer at Manitari Pharma.
Optimind is an emerging provider of psychedelic therapy focusing on two key business verticals: its ReadyToGo Clinic in London, ON, with plans for future locations; and, Psilocybin research via its joint venture with Manitari Pharma, a First Nations focused company whose mission is to provide care to the First Nations community.
Optimind offers psychedelic-assisted treatment to patients suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine assisted treatment and other psychedelic enhanced psychotherapy modalities.
The joint venture with Manitari Pharma aims to help bring awareness to the benefits of psychedelic-assisted psychotherapy and advocate for federal approvals to treat depression and anxiety which remains a disproportionately large issue for the indigenous community. There is an urgent need to address the rates of depression, PTSD, anxiety, phobias and addictions in First Nations communities. Suicide rates due to mental illness among First Nations Communities, Metis, and Inuit have shown to be three times higher than anyone else in North America.
Optimind is an emerging provider of psychedelic therapies. We help people suffering from PTSD, Anxiety, Depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities so that they can heal and live life fully. We are also partnered with developers of psilocybin-associated treatments to further expand our treatment and program offerings. For more information, visit www.Optimindpharma.com.
Caution regarding Forward Looking Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19;risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
For more information, please contact:
Chief Executive Officer